^
    Back
    Association details:
    Biomarker:EGFR exon 19 deletion + BRAF G464A
    Cancer:Lung Adenocarcinoma
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Clin Cancer Res
    Title:

    Modeling clinical responses to targeted therapies by patient-derived organoids of advanced lung adenocarcinoma

    Published date:
    06/03/2021
    Excerpt:
    Eighty-four organoids were established from patients with advanced lung adenocarcinoma….YUO-071 harboring an EGFR exon 19 deletion and a BRAF G464A mutation and the matching patient responded to dabrafenib/trametinib combination therapy.
    DOI:
    10.1158/1078-0432.CCR-20-5026